Sign In
Buy SNDX
$19.05
-0.430 (-2.21%)
At Close: Jul 31, 2026
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
05:58pm, Saturday, 21'st Mar 2026
Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter. Meanwhile, t
Syndax Pharma: Two Drug Launches Fuel Transformational Growth
02:12pm, Wednesday, 18'th Mar 2026
Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to acce
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX
04:08am, Sunday, 15'th Mar 2026
Apis Capital Advisors LLC purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) during the third quarter, according to its most recent 13F filing with the Securities and Ex
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
09:09am, Friday, 13'th Mar 2026
Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
02:22pm, Thursday, 12'th Mar 2026
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
11:17am, Monday, 09'th Mar 2026
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 04'th Mar 2026
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1,
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
10:47pm, Thursday, 26'th Feb 2026
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
07:01pm, Thursday, 26'th Feb 2026
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $1.1 per share a year ago.
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:01pm, Thursday, 26'th Feb 2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 –
Syndax Announces Participation in March Investor Conferences
07:00am, Monday, 23'rd Feb 2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
07:00am, Thursday, 19'th Feb 2026
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will repo
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026
05:44am, Thursday, 12'th Feb 2026
Syndax Pharmaceuticals (SNDX) demonstrates strong commercial momentum with Revuforj and Niktimvo, driving notable revenue growth post-FDA approvals. Revuforj's 4Q25 net revenue surged 38% QoQ to $44M,
Insider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CFO Sells $42,930.84 in Stock
06:18am, Monday, 09'th Feb 2026
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX - Get Free Report) CFO Keith Goldan sold 2,082 shares of the company's stock in a transaction that occurred on Friday, February 6th. The shares were sold at
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
07:00am, Thursday, 05'th Feb 2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. M
